Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: Limited data exists comparing the efficacy of novel therapies containing brentuximab vedotin and/or checkpoint inhibitors to standard chemotherapy as treatment for relapsed/refractory classical Hodgkin Lymphoma. METHODS: In this study, we evaluated outcomes of 162 patients receiving second-line therapy, of which 64% (n = 104) were in the chemotherapy cohort and 36% (n = 58) in the novel therapy cohort. RESULTS: Over all responses for novel therapy and chemotherapy cohort were 76% versus 70% (P = .44), and complete response (CR) rates were 57% versus 46% (P = .40). The 2-year EFS rates were 72% versus 60% in novel therapy and chemotherapy cohort, respectively (P = .10). For patients who proceeded to autologous stem cell transplant (ASCT; n = 135), pretransplant CR predicted improved progression-free survival. In patients not proceeding to ASCT, prolonged 2-year EFS (86% vs. 33%, P < .01) was observed in those receiving novel therapy as second-line treatment. CONCLUSIONS: These data suggest improved outcomes in patients who receive novel agents compared to chemotherapy during second-line treatment.